Best pharmaceutical stocks
Updated November 16, 2026
We cover 475 US-listed pharmaceutical companies. The largest is ELI LILLY & Co (LLY), worth $1.36T. These are the 20 with the highest analysis scores today.
| # | Company | Market cap | Upside to fair value | Dividend | Score |
|---|---|---|---|---|---|
| 1 | UNITED THERAPEUTICS CorpUTHR | $25.2B | -45% | — | 4.0 |
| 2 | ELI LILLY & CoLLY | $1.36T | -37% | 0.5% | 3.4 |
| 3 | Novo Nordisk A SNVO | $184.3B | -37% | 4.3% | 3.4 |
| 4 | Zoetis Inc.ZTS | $34.1B | -21% | 2.5% | 3.4 |
| 5 | Regeneron Pharmaceuticals, Inc.REGN | $98.8B | +17% | 0.4% | 3.2 |
| 6 | Aurinia Pharmaceuticals Inc.AUPH | $2.1B | -6% | — | 3.2 |
| 7 | GSK plcGSK | $102.0B | +31% | 3.6% | 3.0 |
| 8 | Merck & Co., Inc.MRK | $364.3B | -31% | 2.3% | 2.8 |
| 9 | Astrazeneca PLCAZN | $286.0B | -38% | 1.7% | 2.8 |
| 10 | SanofiSNY | $118.0B | +19% | 5.0% | 2.8 |
| 11 | Corcept Therapeutics Inc.CORT | $8.0B | +68% | — | 2.8 |
| 12 | Acadia Pharmaceuticals Inc.ACAD | $3.2B | -33% | — | 2.8 |
| 13 | Johnson & JohnsonJNJ | $687.9B | -39% | 1.9% | 2.6 |
| 14 | Vertex Pharmaceuticals Inc. / MAVRTX | $136.6B | -53% | — | 2.4 |
| 15 | Bristol Myers Squibb Co.BMY | $129.7B | -2% | 4.0% | 2.4 |
| 16 | Alnylam Pharmaceuticals, Inc.ALNY | $22.1B | +34% | — | 2.4 |
| 17 | Grifols SAGRFS | $6.0B | +25% | 1.2% | 2.4 |
| 18 | Organon & Co.OGN | $3.7B | +93% | 0.6% | 2.4 |
| 19 | Pfizer Inc.PFE | $164.7B | -31% | 5.9% | 2.2 |
| 20 | Royalty Pharma plcRPRX | $39.8B | +20% | 1.4% | 2.2 |
A closer look at the top three
UNITED THERAPEUTICS Corp (UTHR): It has revenue growth of 18% a year over three years, an average net margin of 42%, a P/E of about 22, an intrinsic value about 45% below the current price and an overall score of 4.0 out of 5 (strong company).
ELI LILLY & Co (LLY): It has revenue growth of 32% a year over three years, an average net margin of 24%, a P/E of about 47, an intrinsic value about 37% below the current price and an overall score of 3.4 out of 5 (good, with some weak spots).
Novo Nordisk A S (NVO): It has revenue growth of 24% a year over three years, an average net margin of 35%, a P/E of about 11, an intrinsic value about 37% below the current price and an overall score of 3.4 out of 5 (good, with some weak spots).
Frequently asked questions
What is the best pharmaceutical stock right now?
By today’s analysis score, UNITED THERAPEUTICS Corp (UTHR) ranks first with 4.0 out of 5. A score is one measure and does not replace a full analysis.
How many pharmaceutical stocks are listed in the US?
Our data covers 475 pharmaceutical companies, each with its own analysis page.
How is the 0–5 score calculated?
Each stock faces five numeric tests in each of five areas (value, future, past, financial health and shareholder returns); the overall score is the average of the five.
More lists and tools
Lists are generated automatically from SEC filings and market prices and rebuilt every day. They are a starting point for research, not a recommendation to buy or sell.